Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) is a phase 3 interventional study registered as NCT06170788 by Merck Sharp & Dohme LLC, with 614 participants planned, started 2023-12-15 and due to reach its primary completion in 2028-01-25. Interventions recorded: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Sacituzumab tirumotecan, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Sacituzumab tirumotecan, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.